Join        Login             Stock Quote

Oxygen Biotherapeutics (OXBT) Gains After Skin Cream Study Results

 May 31, 2012 12:54 PM

(By Balaseshan) Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) shares jumped after the developer of medical and cosmetic products' Dermacyte Concentrate skin cream lowered histamine-induced itch (pruritus), which was shown in a clinical study data.

The company said data from its clinical study to determine the efficacy of Dermacyte in relieving histamine-induced pruritus show that Dermacyte elicited a significantly larger reduction in Visual Analogue Scale scores after a standard histamine skin prick compared to placebo.

The primary objective of this study was to assess the potential for Dermacyte Concentrate skin cream to reduce the itch (pruritus) and accompanying redness and swelling that occur in histamine-mediated allergic skin reactions.

[Related -Draghi’s Statement Pushes U.S. Market To A Low; Hot Stocks Of The Day: WPP, T, OXBT, RIMM]

Efficacy of Dermacyte for treating pruritus was assessed as reported by each subject using a Visual Analogue Scale, a validated instrument used to evaluate itch in clinical studies.

Itch is one of the most common skin complaints that doctors receive from patients. Although there are several causes for itch, the release of histamine is often the underlying mechanism.

This study, previously announced in January 2012, was a randomized, double-blind, placebo-controlled study which included 30 healthy male and female volunteers aged 18-65. The clinical trial was conducted at St. John's Medical College Hospital in Bangalore, India, under the direction of the clinical research organization, Max Neeman International.

[Related -Post Market Earning Scan: PDII, OXBT, WAG, CMC, NEOG]

This study was the first of a series of trials Oxygen Biotherapeutics plans to conduct to determine the utility of Dermacyte as a treatment for a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis, atopic dermatitis and acne.

These pruritus study results support the company's overall dermatology program and provide the data needed to support the decision to move forward with a psoriasis study in the near future.

OXBT is trading up 8.95% at $2.07 on Thursday. The stock has been trading between $1.30 and $3.55 for the past 52 weeks.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

article imageThe Single Best Place To Invest Your Money For Retirement

It was never supposed to be this daunting. At least that's what we were read on...

article imageNegative Blowback From Negative Interest Rates

The Federal Reserve is widely expected to leave interest rates unchanged today. But perhaps standing pat read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Earning Scan: TIF, BDR, CMT, PDII, OXBT
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.